omniture
纽欧申医药

Latest News

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a...

2024-05-08 21:00 1470

NeuShen Therapeutics Closes Pre-A Financing with ~$20M

* Closure of pre-A financing round led by LAMPAM Capital * Dual internal discovery platforms of ...

2022-09-29 17:50 1762